YN440415 Ibrutinib deacryloylpiperidin... 330786-24-8

Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5nM.

YN440177 CGI-1746 910232-84-7

CGI-1746 is a potent and highly selective inhibitor of theBtkwith IC50 of 1.9nM.

YN440133 Ibrutinib Racemate 936563-87-0

Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversibleBtkinhibitor with IC50 value of 0.5nM.

YN440006 PCI-33380 1022899-36-0

PCI-33380 is an irreversible Bruton's Tyrosine Kinase(BTK) inhibitor (fluorescent probe).

YN440317 GDC-0834 Racemate 1133432-46-8

GDC-0834 Racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4nM in biochemical and cellular assays, respectively.

YN440316 GDC-0834 1133432-49-1

GDC-0834 is a potent and selectiveBTKinhibitor. GDC-0834 inhibits BTK with an in vitroIC50 of 5.9 and 6.4nM in biochemical and cellular assays, respectively, and in vivoIC50 of 1.1 and 5.6μM in mouse and rat, ...

YN440318 GDC-0834 S-enantiomer 1133432-50-4

GDC-0834 (S-enantiomer) is the S-enantiomer of GDC-0834. GDC-0834 is a potent and selective BTK inhibitor.

YN440371 Spebrutinib 1202757-89-8

Spebrutinib (CC-292, AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

YN440007 CNX-500 1202758-21-1

CNX-500 is a probe consisting of a covalentBtkinhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against Btk(IC50 of 0.5nM) and the ability to form a covalent bond withBtk. CNX-500 has low...

YN440302 CNX-774 1202759-32-7

CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.

YN440044 BMS-935177 1231889-53-4

BMS-935177 is a potent, reversible Bruton's Tyrosine Kinase (BTK) inhibitor with an IC50 value of 2.8 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec fam...

YN440372 RN486 1242156-23-5

RN486 is a potent and selective BTK inhibitor with IC50 of 4 nM.

YN440053 BTK IN-1 1270014-40-8

BTK IN-1 (SNS062 analog) is a potentBTKinhibitor, with an IC50 of <100nM.

YN440387 ONO-4059 (analog) 1351635-67-0

ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.

YN440344 Tirabrutinib 1351636-18-4

Tirabrutinib (ONO-4059) is a highly selective, orally bioavailableBTKinhibitor with an IC50 of 2.2nM.

YN440158 CG-806 1370466-81-1

CG-806 is an orally active, potent and non-covalent pan-FLT3/pan-BTKinhibitor with an IC50 of 0.08 µM forFLT3. CG-806 has an IC50 of 11nM againstFLT3wild type (WT)-transfected Ba/F3 cells.

YN440243 (Rac)-IBT6A 1412418-47-3

(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC...

YN440027 Evobrutinib 1415823-73-2

Evobrutinib is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.

YN440368 Acalabrutinib 1420477-60-6

Acalabrutinib(ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has impro...

YN440393 Fenebrutinib 1434048-34-6

Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91nM, 1.6, 1.3, 12.6, and 3.4nM for WT Btk, and the C481S, C481R, T474I, T474M...